Literature DB >> 15456945

Mitochondrial enzymes in schizophrenia.

Parvesh Bubber1, Jicheng Tang, Vahram Haroutunian, Hui Xu, Kenneth L Davis, John P Blass, Gary E Gibson.   

Abstract

The responses of brain metabolism and blood flow to stimulation are diminished in the dorsolateral prefrontal cortexes (DLPFCs) of schizophrenic patients. Reductions in mitochondrial enzymes underlie diminished metabolism in several neurodegenerative diseases. Thus, we tested whether reductions in selected mitochondrial enzymes could underlie the changes in schizophrenia. The activities of the pyruvate dehydrogenase complex (PDHC), aconitase, isocitrate dehydrogenase (ICDH), and the alpha-ketoglutarate dehydrogenase complex (KGDHC) were determined on DLPFCs from patients with schizophrenia (n=26) and normal nonpsychiatric disease controls (n=13). The enzyme activities (mU/mg protein; mean +/- SEM) were similar (values for controls and schizophrenic patients, respectively) for PDHC (11.36 +/-1.5, 10.33 +/- 0.8), aconitase (1.06 +/- 0.1, 1.35 +/- 0.2), ICDH (31.70 +/- 2.7, 32.00 +/- 2.6), and KGDHC (2.62 +/- 0.4, 3.09 +/- 0.3). Separate analyses of the patients matched for age or postmortem interval gave similar conclusions. Cognitive dementia rating scores correlated poorly with activities of PDHC, aconitase, ICDH, and KGDHC. In one schizophrenic patient, activity of aconitase was undetectable, and in two others KGDHC activity was very low. Both had low activities of ICDH. A reduced activity of these enzymes in a subgroup is consistent with other data, suggesting that some patients with schizophrenia have abnormalities in brain mitochondria. However, in schizophrenia, unlike a number of neurodegenerative diseases, reductions in the activities of the key mitochondrial enzymes KGDHC and PDHC are not frequent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456945     DOI: 10.1385/JMN:24:2:315

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  30 in total

1.  Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia.

Authors:  I Maurer; S Zierz; H Möller
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

2.  Metabolic consequences of the cytochrome c oxidase deficiency in brain of copper-deficient Mo(vbr) mice.

Authors:  W S Kunz; A V Kuznetsov; J F Clark; I Tracey; C E Elger
Journal:  J Neurochem       Date:  1999-04       Impact factor: 5.372

3.  Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia.

Authors:  K F Berman; E F Torrey; D G Daniel; D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1992-12

4.  Cortical cholinergic markers in schizophrenia.

Authors:  V Haroutunian; M Davidson; P D Kanof; D P Perl; P Powchik; M Losonczy; J McCrystal; D P Purohit; L M Bierer; K L Davis
Journal:  Schizophr Res       Date:  1994-05       Impact factor: 4.939

5.  Mitochondrial sequence variants in patients with schizophrenia.

Authors:  E Lindholm; L Cavelier; W M Howell; I Eriksson; P Jalonen; R Adolfsson; D H Blackwood; W J Muir; A J Brookes; U Gyllensten; E E Jazin
Journal:  Eur J Hum Genet       Date:  1997 Nov-Dec       Impact factor: 4.246

6.  Cerebral glucose metabolism in childhood onset schizophrenia.

Authors:  L K Jacobsen; S D Hamburger; J D Van Horn; A C Vaituzis; K McKenna; J A Frazier; C T Gordon; M C Lenane; J L Rapoport; A J Zametkin
Journal:  Psychiatry Res       Date:  1997-10-31       Impact factor: 3.222

7.  Postmortem studies in schizophrenia.

Authors:  P Powchik; M Davidson; V Haroutunian; S M Gabriel; D P Purohit; D P Perl; P D Harvey; K L Davis
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

8.  Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.

Authors:  B V Siegel; M S Buchsbaum; W E Bunney; L A Gottschalk; R J Haier; J B Lohr; S Lottenberg; A Najafi; K H Nuechterlein; S G Potkin
Journal:  Am J Psychiatry       Date:  1993-09       Impact factor: 18.112

9.  Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients.

Authors:  Martin R Gluck; Rohan G Thomas; Kenneth L Davis; Vahram Haroutunian
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

10.  Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features.

Authors:  R E Gur; P D Mozley; S M Resnick; L H Mozley; D L Shtasel; F Gallacher; S E Arnold; J S Karp; A Alavi; M Reivich
Journal:  Arch Gen Psychiatry       Date:  1995-08
View more
  23 in total

1.  Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Authors:  Jeffrey K Yao; George G Dougherty; Ravinder D Reddy; Matcheri S Keshavan; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

2.  Fish oil and antipsychotic drug risperidone modulate oxidative stress in PC12 cell membranes through regulation of cytosolic calcium ion release and antioxidant system.

Authors:  Sevil Altinkiliç; Mustafa Naziroğlu; Abdülhadi Cihangir Uğuz; Ramazan Ozcankaya
Journal:  J Membr Biol       Date:  2010-06-24       Impact factor: 1.843

3.  Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients.

Authors:  P Bubber; V Hartounian; G E Gibson; J P Blass
Journal:  Eur Neuropsychopharmacol       Date:  2010-11-30       Impact factor: 4.600

4.  Glutathione modulates Ca(2+) influx and oxidative toxicity through TRPM2 channel in rat dorsal root ganglion neurons.

Authors:  Mustafa Nazıroğlu; Cemil Özgül; Bilal Çiğ; Salih Doğan; Abdulhadi Cihangir Uğuz
Journal:  J Membr Biol       Date:  2011-07-12       Impact factor: 1.843

5.  Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism.

Authors:  Abha Chauhan; Feng Gu; Musthafa M Essa; Jerzy Wegiel; Kulbir Kaur; William Ted Brown; Ved Chauhan
Journal:  J Neurochem       Date:  2011-02-24       Impact factor: 5.372

Review 6.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

7.  Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  J K Yao; G G Dougherty; R D Reddy; M S Keshavan; D M Montrose; W R Matson; S Rozen; R R Krishnan; J McEvoy; R Kaddurah-Daouk
Journal:  Mol Psychiatry       Date:  2009-04-28       Impact factor: 15.992

8.  Iron overload prevents oxidative damage to rat brain after chlorpromazine administration.

Authors:  Natacha E Piloni; Andres A Caro; Susana Puntarulo
Journal:  Biometals       Date:  2018-05-15       Impact factor: 2.949

9.  Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis.

Authors:  Daniel Martins-de-Souza; Wagner F Gattaz; Andrea Schmitt; Christiane Rewerts; Sérgio Marangoni; José C Novello; Giuseppina Maccarrone; Christoph W Turck; Emmanuel Dias-Neto
Journal:  J Neural Transm (Vienna)       Date:  2008-11-26       Impact factor: 3.575

Review 10.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.